20% of eligible patients receive shingles vaccine within six months of NIP change
Monthly shingles vaccinations have soared from 30,000 to 200,000 since the National Immunisation Program replaced the live-attenuated Zostavax with recombinant vaccine Shingrix, data show.
Until November 2023, around 15,000 Zostavax doses were being administered monthly under the National Immunisation Program (NIP), alongside a similar number of privately sourced Shingrix vaccines, which cost up to $600 for the two-dose course.